BG107447A - Приложение на щамове parapoxvirus ovis при органни фибрози - Google Patents

Приложение на щамове parapoxvirus ovis при органни фибрози Download PDF

Info

Publication number
BG107447A
BG107447A BG107447A BG10744703A BG107447A BG 107447 A BG107447 A BG 107447A BG 107447 A BG107447 A BG 107447A BG 10744703 A BG10744703 A BG 10744703A BG 107447 A BG107447 A BG 107447A
Authority
BG
Bulgaria
Prior art keywords
manufacture
fibrosis
liver
organ fibrosis
preventive
Prior art date
Application number
BG107447A
Other languages
Bulgarian (bg)
English (en)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of BG107447A publication Critical patent/BG107447A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG107447A 2000-07-11 2003-01-08 Приложение на щамове parapoxvirus ovis при органни фибрози BG107447A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (fr) 2000-07-11 2001-07-11 Utilisation de souches du virus parapox ovis contre la fibrose des organes

Publications (1)

Publication Number Publication Date
BG107447A true BG107447A (bg) 2003-09-30

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107447A BG107447A (bg) 2000-07-11 2003-01-08 Приложение на щамове parapoxvirus ovis при органни фибрози

Country Status (30)

Country Link
US (1) US6632647B2 (fr)
EP (1) EP1303302B1 (fr)
JP (1) JP5106736B2 (fr)
CN (1) CN1452496B (fr)
AR (1) AR028800A1 (fr)
AU (2) AU8582701A (fr)
BG (1) BG107447A (fr)
CA (1) CA2415399C (fr)
CZ (1) CZ200372A3 (fr)
DK (1) DK200300014A (fr)
EE (1) EE200300019A (fr)
FI (1) FI20030038A (fr)
GB (1) GB2383752B (fr)
HK (1) HK1054330B (fr)
HR (1) HRP20030097A2 (fr)
HU (1) HU227668B1 (fr)
IL (1) IL153826A0 (fr)
LT (1) LT5064B (fr)
LU (1) LU90996B1 (fr)
LV (1) LV12991B (fr)
MA (1) MA25765A1 (fr)
MX (1) MXPA03000278A (fr)
NO (1) NO20030081L (fr)
NZ (1) NZ523535A (fr)
PL (1) PL360839A1 (fr)
RU (1) RU2003104522A (fr)
SE (1) SE0300033L (fr)
SI (1) SI21171A (fr)
SK (1) SK382003A3 (fr)
WO (1) WO2002004019A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6844000B2 (en) 2001-12-07 2005-01-18 Bayer Pharmaceuticals Corporation Use of Parapox B2L protein to treat cancer and modify immune responses
EP1574211A1 (fr) 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
WO2012045473A1 (fr) * 2010-10-07 2012-04-12 Technische Universität München Virus pour le traitement d'une fibrose
WO2017141942A1 (fr) * 2016-02-16 2017-08-24 国立大学法人大阪大学 Composition médicinale pour le traitement de la fibrose
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE203678T1 (de) * 1996-04-15 2001-08-15 Anton Prof Dr Med Vet Dr Mayr Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
NO20030081D0 (no) 2003-01-08
GB2383752A (en) 2003-07-09
GB2383752B (en) 2004-11-24
SE0300033D0 (sv) 2003-01-10
US20020076418A1 (en) 2002-06-20
FI20030038A (fi) 2003-03-10
NO20030081L (no) 2003-01-08
MA25765A1 (fr) 2003-04-01
PL360839A1 (en) 2004-09-20
HUP0303830A2 (hu) 2004-04-28
SK382003A3 (en) 2003-07-01
HK1054330A1 (en) 2003-11-28
JP5106736B2 (ja) 2012-12-26
HUP0303830A3 (en) 2004-10-28
HRP20030097A2 (en) 2005-02-28
CN1452496B (zh) 2012-10-10
WO2002004019A2 (fr) 2002-01-17
CA2415399A1 (fr) 2003-01-08
HU227668B1 (en) 2011-11-28
IL153826A0 (en) 2003-07-31
LT5064B (lt) 2003-11-25
EP1303302B1 (fr) 2009-10-14
LT2003008A (en) 2003-07-25
WO2002004019A3 (fr) 2002-08-01
LU90996B1 (en) 2003-01-08
AU2001285827B2 (en) 2006-11-30
HK1054330B (zh) 2005-07-15
SE0300033L (sv) 2003-03-10
CZ200372A3 (cs) 2003-05-14
GB0302629D0 (en) 2003-03-12
LV12991B (en) 2003-08-20
NZ523535A (en) 2004-12-24
DK200300014A (da) 2003-03-07
CN1452496A (zh) 2003-10-29
EP1303302A2 (fr) 2003-04-23
AR028800A1 (es) 2003-05-21
CA2415399C (fr) 2011-11-08
RU2003104522A (ru) 2004-06-27
AU8582701A (en) 2002-01-21
SI21171A (sl) 2003-10-31
JP2004502741A (ja) 2004-01-29
EE200300019A (et) 2004-10-15
US6632647B2 (en) 2003-10-14
MXPA03000278A (es) 2004-04-05

Similar Documents

Publication Publication Date Title
KR0149677B1 (ko) 안정화된 생 백신
EP0696326B1 (fr) Utilisation de NDV pour la fabrication d'un médicament destiné au traitement de cancer
Arakawa et al. Antiviral and virucidal activities of natural products
BG107447A (bg) Приложение на щамове parapoxvirus ovis при органни фибрози
JP5950964B2 (ja) 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
KR102353119B1 (ko) 시아노박테리아 추출물, 이의 제조 방법 및 그 용도
JP7399976B2 (ja) Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用
CN114377127A (zh) 一种三联卵黄抗体制剂及其制备方法和应用
TWI359669B (fr)
WO2022000167A1 (fr) Utilisation de transferrine, d'un récepteur de transferrine et d'un anticorps de celui-ci dans la préparation d'un médicament pour résister au virus sars-cov-2
EP4248986A1 (fr) Utilisation d'un polypeptide ayant une activité superoxyde dismutase et de vésicules extracellulaires pour le traitement ou la prévention d'une infection respiratoire virale
CN106581052B (zh) 柠檬酸根离子和铁离子在抑制rna病毒中的应用
TWI803229B (zh) 一種化合物tsyi-zac用於抑制登革熱病毒感染及其醫藥治療用途
TWI807609B (zh) 乳酸菌用於提升對腸病毒71型之抵抗力之用途
TWI817332B (zh) 乳酸菌用於提升對腸病毒71型之抵抗力之用途
CN109550041B (zh) 奥利万星磷酸盐在制备防治牛传染性鼻气管炎药物中的应用
CN117018034A (zh) 胎盘源细胞因子在治疗和预防疱疹病毒感染及其相关疾病的应用
CN115475196A (zh) 腹安颗粒浸膏在制备用于治疗手足口病的药物中的用途
CN116987171A (zh) 一种用于防治疱疹病毒感染的胎盘源细胞因子制备方法及其制剂的应用
CN117122693A (zh) 经酸酐修饰的蛋白质抑制痘病毒的方法
Vivo Functional Antagonism of Chemokine
Kriek The oncolytic properties of two newcastle disease virus strains